Aclarion, Inc. (ACON): R&D Expense
$1.03M
Year ended 2025-12-31
$1.18M
Trailing 12 months to 2026-06-30
-1.1%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.03M | +16.3% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $888.8K | +1.8% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $873.3K | -18.2% | 2025-04-09, From 2023-01-01 |
| 2022-12-31 | $1.07M | +35.6% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $787.9K | n/a | 2023-06-12, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aclarion, Inc. (ACON) | 2025-12-31 | $1.03M | +16.3% |
| Sera Prognostics, Inc. (SERA) | 2025-12-31 | $13.17M | -10.6% |
| YD Bio Ltd (YDES) | 2025-12-31 | $1.60M | +226.1% |
| BioNexus Gene Lab Corp (BGLC) | 2025-12-31 | $50.7K | +6.6% |
| Exagen Inc. (XGN) | 2025-12-31 | $6.25M | +16.4% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $50.26M | +2.8% |
| Biodesix Inc (BDSX) | 2025-12-31 | $12.00M | +25.5% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
Compare ACON, SERA, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗